Ketryx, a company specializing in agentic continuous compliance platforms for safety-critical product development, announced that William A. Hawkins, former Chairman and CEO of Medtronic, has joined its Board of Directors. Hawkins also participated in the company’s Series B financing, signaling strong industry confidence in Ketryx’s approach to regulatory compliance in the life sciences sector.
Ketryx helps companies in safety-critical industries—including medical devices, pharmaceuticals, and robotics—accelerate product development by automatically generating compliant documentation, maintaining continuous traceability, and enabling safe and verifiable AI at scale within the tools teams already use. The platform overlays existing workflows to automate documentation, create traceability, and accelerate release cycles without disrupting established processes. According to the company, its AI agents can reduce manual work by up to 90 percent and help teams identify and close compliance gaps, improving both speed and quality across the product lifecycle.
The appointment of Hawkins, a veteran leader in the medical technology industry, underscores the growing importance of integrating AI into regulated environments while maintaining rigorous compliance. During his tenure at Medtronic, Hawkins oversaw significant growth and innovation, and his expertise is expected to guide Ketryx as it expands its footprint among life sciences firms. The company is already trusted by four of the world's top five medical device manufacturers.
“Ketryx is addressing a critical bottleneck in life sciences: the challenge of incorporating AI into product development while meeting stringent regulatory requirements,” said a company representative. Hawkins’ addition to the board is poised to help Ketryx navigate the complex landscape of medical device regulations and accelerate adoption of its platform across the industry.
The move comes as regulatory bodies worldwide increasingly scrutinize AI-based systems in healthcare. By automating compliance documentation and traceability, Ketryx aims to reduce the time and cost associated with bringing new medical devices and pharmaceuticals to market. This could have significant implications for patients, who may gain faster access to innovative treatments, and for companies, which face mounting pressure to demonstrate safety and efficacy in an AI-driven era.
For more information, visit www.ketryx.com.
